At a glance
ClinicalIndex Comparison RecordPhase 2Active· 35 enrolled
Drug / intervention
Trametinib Dimethyl Sulfoxidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MATCH Treatment Subprotocol R: Phase II Study of Trametinib in Patients With BRAF Fusions, or With NonV600E, Non-V600K BRAF Mutations
In Brief
A Phase 2 clinical trial evaluating Trametinib Dimethyl Sulfoxide for Advanced Lymphoma and 5 related conditions. Active but no longer recruiting, targeting 35 participants across 1 site.
Detailed Summary
This phase II MATCH treatment trial identifies the effects of trametinib in patients with cancer having genetic changes called BRAF mutations and fusions. Trametinib may block proteins called MEK1 and MEK2, which may be needed for growth of cancer cells that express BRAF mutations. Researchers hope to learn if giving trametinib will shrink this type of cancer or stop its growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2Active
201620172018201920202021202220232024202520262027
Enrollment StartAug 2015
Primary CompletionMar 2019
First PostedJun 2020
TodayJul 2026
Study CompletionMar 2027
First PostedJun 19, 2020
Enrollment StartAug 12, 2015
Primary CompletionMar 18, 2019
Study CompletionMar 31, 2027
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 6.0 years ago
Interventions
Trametinib Dimethyl Sulfoxidedrug
Given PO